Luteinizing hormone-releasing hormone analogs with increased anti-ovulatory activity

A series of LH-RH antagonist analogs has been developed in which inhibitory activities have been increased to a potentially clinically useful level. The new peptides, which are typified by [N-acetyl-D-p-Cl-Phe 1,2, D-Trp 3, D-Phe 6,D-Ala 10]-LH-RH and [N-acetyl-D-Trp 1,3,D-p-Cl-Phe 2,D-Phe 6, D-Ala 10]-LH-RH, most importantly contain new modification to positions 1, 2 and 10, and induce full blockade of ovulation at single doses as low as 10 μg per rat (50 μg/kg). Various ring substituents on D-Trp or D-Phe in position 1 or other D-amino acid replacements in position 10 did not significantly improve anti-ovulatory activity. Incorporation of N-Me-Leu in position 7 was slightly detrimental to activity

Biogenic Magnetite Nanoparticle Ensemble Use in MRI Diagnostics

We present a simple analytical tool, which allows the calculation of the MRI diagnostics feasibility of the biogenic magnetite nanoparticles. Elevated levels of these particles are usually linked to the pathological processes, especially to neurodegenerative disorders. We showed theoretically that the biogenic magnetite itself is not sufficient for the non-invasive diagnostics and must be extended with the total iron incorporated in other biological structures

ChemInform Abstract: SYNTHESIS OF D-PHE2, PHE3, D-PHE6-LH-RH, A POTENT INHIBITOR OF LH-RH

Die beiden Pentapeptide (I) und (II), deren Darstellung stufenweise unter Verwendung verschiedener Kupplungsmethoden erfolgt, werden nach der Azid‐Methode ko densiert

Comparison of Iron Oxide-Related MRI Artifacts in Healthy and Neuropathological Human Brain Tissue

The aim of this study is to clarify whether clinical magnetic resonance imaging data can be utilised to evaluate the pathological processes associated with disrupted iron homeostasis, such as neurodegenerative processes or cirrhosis. Although MRI has the potential to become a non-invasive biomarker of such pathology, new quantification methods must be introduced. Our findings confirmed that it is possible to detect significant difference between healthy and pathological tissue from standard T2 weighted MRI protocols

Risk of Hospitalization Associated With Body Mass Index and Weight Changes Among Prevalent Haemodialysis Patients

The impact of body mass index (BMI) and body weight on hospitalization rates in haemodialysis patients is unknown. This study hypothesizes that being either underweight or obese is associated with a higher hospitalization rate. Observational study of 6296 European haemodialysis patients with prospective data collection and follow-up every six months for three years (COSMOS study). The risk of being hospitalized was estimated by a time-dependent Cox regression model and the annual risk (incidence rate ratios, IRR) by Poisson regression. We considered weight loss, weight gain and stable weight. Weight change analyses were also performed after patient stratification according to their baseline BMI. A total of 3096 patients were hospitalized at least once with 9731 hospitalizations in total. The hospitalization incidence (fully adjusted IRR 1.28, 95% CI [1.18-1.39]) was higher among underweight patients (BMI <20kg/m2) than patients of normal weight (BMI 20-25kg/m2), while the incidence of overweight (0.88 [0.83-0.93]) and obese patients (≥30kg/m2, 0.85 [0.79-0.92]) was lower. Weight gain was associated with a reduced risk of hospitalization. Conversely, weight loss was associated with a higher hospitalization rate, particularly in underweight patients (IRR 2.85 [2.33-3.47]). Underweight haemodialysis patients were at increased risk of hospitalization, while overweight and obese patients were less likely to be hospitalized. Short-term weight loss in underweight individuals was associated with a strikingly high hospitalization rate.info:eu-repo/semantics/publishedVersio